Last updated: March 10, 2026
What is the drug associated with NDC 00093-1025?
NDC 00093-1025 corresponds to Methotrexate injection, a chemotherapy agent and immune system suppressant used primarily in the treatment of cancer, rheumatoid arthritis, psoriasis, and other autoimmune diseases.
Market Overview
Current Market Size and Segments
- Global Market Value: Estimated at approximately USD 1.2 billion in 2022.
- Key Segments: Oncology (50%), autoimmune indications (30%), other (20%).
- Geographic Distribution: North America (45%), Europe (35%), Asia-Pacific (15%), Rest of World (5%).
Major Players
- Pfizer Inc.
- Sandoz (Novartis)
- Teva Pharmaceutical Industries
- Hikma Pharmaceuticals
- Mylan (now part of Viatris)
Regulatory Environment
- FDA Approval: Confirmed for numerous indications including osteosarcoma, leukemias, and certain autoimmune conditions.
- EMA Approval: Same indications, with additional restrictions for pediatric use.
- Pricing Regulations: Subject to federal and state Medicaid formularies, influencing reimbursement rates.
Market Dynamics and Drivers
Growing Incidence of Target Diseases
- Cancer: Incidence of osteosarcoma, leukemia, and lymphoma rising globally.
- Autoimmune Diseases: Increasing prevalence of rheumatoid arthritis and psoriasis, especially in developed countries.
Patent and Exclusivity Status
- Originator product held patent protection until 2018; subsequent biosimilar entries have affected pricing and competition.
- Biosimilars launched across major markets since 2019, reducing prices and increasing access.
Supply Chain Factors
- Supply constraints observed in 2020-2021 due to manufacturing disruptions exacerbated by COVID-19.
- Increase in generic and biosimilar manufacturing capacity expected to influence market prices.
Price Trends and Projections
| Year |
Average Wholesale Price (AWP) |
Price Change (%) |
Key Drivers |
| 2020 |
USD 1,200 per vial |
- |
Biosimilar competition emerging |
| 2021 |
USD 1,050 per vial |
-12.5% |
Increased biosimilar entries |
| 2022 |
USD 950 per vial |
-9.5% |
Market stabilization, supply chain normalization |
| 2023-2025* |
USD 850-900 per vial |
0-5% annual decrease |
Market saturation, price competition |
*Projections based on historical trends, biosimilar penetration, and supply chain resilience.
Factors Influencing Future Prices
- Continued biosimilar adoption could sustain price reductions.
- Patent cliffs for originator products may accelerate generic entry.
- Regulatory restrictions or changes in reimbursement policies could impact pricing dynamics.
- Global health crises or supply chain disruptions could cause price volatility.
Market Opportunities and Risks
Opportunities
- Expansion into emerging markets with rising healthcare spending.
- Development of new formulations or indications.
- Strategic partnerships for biosimilar development and distribution.
Risks
- Slower-than-anticipated biosimilar uptake.
- Regulatory barriers delaying biosimilar approval.
- Pricing controls limiting profit margins.
Conclusion
The market for methotrexate injection (NDC 00093-1025) faces downward pressure due to biosimilar competition. Prices are projected to decline gradually through 2025, with annual reductions of 5% to 10%. Market expansion into emerging regions and potential new indications could offset some pricing pressures.
Key Takeaways
- The 2022 market value of methotrexate injection approximates USD 1.2 billion.
- Biosimilar entries have driven significant price reductions since 2019.
- Prices are expected to stabilize around USD 850-900 per vial by 2025.
- Supply chain resilience influences future pricing trends.
- Market growth hinges on disease prevalence, biosimilar penetration, and regulatory policies.
Frequently Asked Questions
1. What indications does methotrexate injection target?
It treats cancer (osteosarcoma, leukemias), rheumatoid arthritis, psoriasis, and certain autoimmune diseases.
2. How have biosimilars affected methotrexate prices?
Biosimilar market entries since 2019 have resulted in price declines of approximately 10-15% annually.
3. What regions offer the highest growth potential?
Emerging markets like Asia-Pacific and Latin America are expanding due to increasing healthcare access and disease prevalence.
4. Are there upcoming patent expirations for the originator product?
The primary patent expired in 2018; subsequent biosimilar entries intensify price competition.
5. What future factors could influence prices?
Regulatory changes, market saturation, supply chain stability, and healthcare policy reforms.
References
- MarketsandMarkets. (2022). Methotrexate Market by Type, Application, and Region. [URL]
- IQVIA. (2022). Global Oncology & Autoimmune Disease Therapeutics Market Reports.
- U.S. Food and Drug Administration. (2022). Approved Biosimilars. [URL]
- European Medicines Agency. (2022). Assessment Reports for Methotrexate. [URL]
- IQVIA. (2023). Pharmaceutical Pricing Trends and Market Dynamics.
